Opinion|Videos|November 15, 2024
Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions
Key Takeaways
- Management options for nmCSPC include active surveillance, radiotherapy, surgery, and systemic therapy, guided by NCCN recommendations.
- High-volume symptomatic patients with minimal comorbidities may benefit from triplet therapy, including docetaxel, darolutamide, and androgen deprivation therapy.
Panelists discuss how management options for nonmetastatic castration-sensitive prostate cancer (nmCSPC) include active surveillance, radiotherapy, and systemic therapy, with recommendations influenced by factors such as tumor volume, prostate-specific antigen (PSA) doubling time, and patient life expectancy, particularly for those with high-volume symptomatic disease.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What management options are available for nmCSPC? What factors influence whether you recommend active surveillance vs active treatment?
- National Comprehensive Cancer Network (NCCN) recommendations (active surveillance, radiotherapy, surgery, systemic therapy) (
NCCN, Prostate Cancer, v4.2024 ;Moreira et al, Cancer Manag Res, 2021 ) - Patients with high-volume symptomatic disease, without significant comorbidities, and long life expectancy could receive triplet therapy ofdocetaxel, darolutamide, and androgen deprivation therapy (ARASENS trial:
Hussain et al, J Clin Oncol, 2023 ; PEACE-1 trial:Bossi et al. J Clin Oncol, 2023 )
- National Comprehensive Cancer Network (NCCN) recommendations (active surveillance, radiotherapy, surgery, systemic therapy) (
- Role of the multidisciplinary care team in patient management
- Practical considerations: tumor volume, PSA/PSA doubling time
- Biochemical recurrence (BCR): PSA doubling time less than 12 months considered at high risk for rapid disease progression and death (
Markowski et al, Clin Gen Cancer, 2019 ) - Treatment considerations in trying to delay progression, 30% with BCR will develop metastatic disease (
Antonarakis et al, BJU Int, 2012 )- How can progression to metastatic disease be delayed?
Advertisement
Related to this article
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
4
ESMO 2026: Key presentations across genitourinary oncology
5